[{"id":"35c5e79b-54b0-43e1-b61a-1b50d58d242e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06725173","created_at":"2025-02-25T14:43:58.802Z","updated_at":"2025-02-25T14:43:58.802Z","phase":"","brief_title":"Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.","source_id_and_acronym":"NCT06725173","lead_sponsor":"University of Washington","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-14"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"2d78abd7-6d51-41e8-9d45-561b60e6b952","acronym":"HAMMER I","url":"https://clinicaltrials.gov/study/NCT05169957","created_at":"2021-12-27T15:54:22.593Z","updated_at":"2024-07-02T16:34:59.720Z","phase":"Phase 1","brief_title":"Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)","source_id_and_acronym":"NCT05169957 - HAMMER I","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 06/13/2023","primary_completion_date":" 06/13/2023","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2024-05-31"},{"id":"f270357c-b837-458a-950f-910b0ee31575","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587352","created_at":"2023-11-26T19:51:41.019Z","updated_at":"2024-07-02T16:35:00.381Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01587352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • BAP1 • GNA11","pipe":"","alterations":" ","tags":["GNAQ • BAP1 • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/29/2012","start_date":" 05/29/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"a4243371-e966-46ad-813b-48b6cc83f0e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858869","created_at":"2021-01-18T14:01:58.994Z","updated_at":"2025-02-25T16:05:04.203Z","phase":"Phase 1","brief_title":"Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases","source_id_and_acronym":"NCT02858869","lead_sponsor":"Emory University","biomarkers":" PD-L1 • BRAF • ALK","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/04/2016","start_date":" 10/04/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 10/28/2023","study_completion_date":" 10/28/2023","last_update_posted":"2024-05-13"},{"id":"e6a761ac-dd0a-4052-9115-9278013bbd57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02519322","created_at":"2021-01-18T12:10:30.425Z","updated_at":"2025-02-25T16:30:41.228Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Checkpoint Blockade","source_id_and_acronym":"NCT02519322","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 02/02/2016","start_date":" 02/02/2016","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 01/26/2023","study_completion_date":" 01/26/2023","last_update_posted":"2024-04-05"},{"id":"69f4b805-c2c3-43d2-9b60-e7eeb5a44a5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00020267","created_at":"2021-01-17T23:57:22.941Z","updated_at":"2024-07-02T16:35:16.525Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Metastatic Cancer","source_id_and_acronym":"NCT00020267","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-04"},{"id":"717e3712-78d8-4f21-ab42-1fd6c0efe2e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01334008","created_at":"2021-01-18T05:26:18.539Z","updated_at":"2024-07-02T16:35:21.523Z","phase":"","brief_title":"Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma","source_id_and_acronym":"NCT01334008","lead_sponsor":"Institut Curie","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2024-01-31"},{"id":"2a13790b-df30-4d16-94bd-4e9b80cce1c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098210","created_at":"2021-10-28T17:56:20.511Z","updated_at":"2024-07-02T16:35:22.189Z","phase":"Phase 1","brief_title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer","source_id_and_acronym":"NCT05098210","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • BRAF • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • BRAF • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"},{"id":"4d03b67b-68b2-483a-a512-97aaeedafd94","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865212","created_at":"2021-01-18T19:03:32.995Z","updated_at":"2024-07-02T16:35:24.120Z","phase":"Phase 1","brief_title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT03865212","lead_sponsor":"Mayo Clinic","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VSV-IFNbetaTYRP1 • Voyager-V1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 01/20/2027","primary_completion_date":" 01/20/2027","study_txt":" Completion: 01/20/2027","study_completion_date":" 01/20/2027","last_update_posted":"2024-01-09"},{"id":"af094930-141f-44cb-99b2-08d2ebb813d2","acronym":"AMUM","url":"https://clinicaltrials.gov/study/NCT05502900","created_at":"2022-08-16T11:56:19.168Z","updated_at":"2024-07-02T16:35:28.240Z","phase":"Phase 3","brief_title":"Adjuvant Melatonin for Uveal Melanoma","source_id_and_acronym":"NCT05502900 - AMUM","lead_sponsor":"Gustav Stalhammar","biomarkers":" BAP1","pipe":"","alterations":" ","tags":["BAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/02/2022","start_date":" 10/02/2022","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2023-11-22"},{"id":"12fc1d17-0a06-4691-bf0b-18767b9a6e88","acronym":"Mel66","url":"https://clinicaltrials.gov/study/NCT04364230","created_at":"2021-01-18T21:05:35.842Z","updated_at":"2024-07-02T16:35:33.934Z","phase":"Phase 1/2","brief_title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","source_id_and_acronym":"NCT04364230 - Mel66","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" BRAF • CD4 • FOXP3","pipe":"","alterations":" ","tags":["BRAF • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-11"},{"id":"12bdd7c1-fcfb-4492-93a6-624b6e9c7434","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835145","created_at":"2021-01-18T08:10:09.271Z","updated_at":"2024-07-02T16:36:06.016Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01835145","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/31/2013","start_date":" 07/31/2013","primary_txt":" Primary completion: 10/21/2016","primary_completion_date":" 10/21/2016","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2022-08-04"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"743f2392-3b37-49eb-aa59-6285b6c06740","acronym":"","url":"https://clinicaltrials.gov/study/NCT00121225","created_at":"2021-01-18T00:24:32.398Z","updated_at":"2024-07-02T16:37:03.407Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma","source_id_and_acronym":"NCT00121225","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TFF1","pipe":"","alterations":" ","tags":["TFF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2019-01-29"},{"id":"30af6c5b-69c6-4fd7-9cfb-43b1da4df1b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01200238","created_at":"2021-01-18T04:48:32.724Z","updated_at":"2024-07-02T16:37:05.964Z","phase":"Phase 2","brief_title":"STA-9090(Ganetespib) in Metastatic Ocular Melanoma","source_id_and_acronym":"NCT01200238","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MET • HSP90AA1","pipe":" | ","alterations":" MET expression","tags":["MET • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/12/2014","primary_completion_date":" 10/12/2014","study_txt":" Completion: 11/11/2016","study_completion_date":" 11/11/2016","last_update_posted":"2018-10-18"},{"id":"b28bc4bf-2724-470d-a200-8e1a03612399","acronym":"","url":"https://clinicaltrials.gov/study/NCT01143402","created_at":"2021-01-17T17:53:31.374Z","updated_at":"2024-07-02T16:37:19.584Z","phase":"Phase 2","brief_title":"Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01143402","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • GNA11 • CYP1A2","pipe":" | ","alterations":" GNAQ mutation","tags":["GNAQ • GNA11 • CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Koselugo (selumetinib) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2017-07-26"}]